Method of Predicting Personalized Response to Cancer Therapy, Method of Treating Cancer, and Kit Therefor
a personalized response and cancer therapy technology, applied in the field of oncology, can solve the problems of limiting or counteracting the effectiveness of the treatment with the cancer therapy modality, and achieve the effect of limiting or counteracting the effectiveness of the treatmen
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
example 1
t of Chemotherapy on Circulating Pro-Tumorigenic Factors—a Protein Profiling Approach in Humans
[0126]The aim is to define a profile of circulating factors indicative of a pro-tumorigenic host response to chemotherapy in human cancer patients.
[0127]A total of 16 breast and 19 colorectal cancer patients were recruited to this study. All breast cancer patients received Adriamycin / Cyclophosphamide (AC) chemotherapy, and all colorectal cancer patients received Folinic acid / Fluorouracil / Oxaliplatin (FOLFOX) chemotherapy according to standard regimens at HaEmek Medical Center, Afula, Israel. Blood samples were drawn (into EDTA tubes) from the patients at 2 time points: i) before receiving the first dose of chemotherapy (baseline); ii) 24 hours after receiving the first dose of chemotherapy (post-treatment). Plasma samples were prepared from whole blood by centrifugation at 1300 g for 10 min at room temperature. Supernatants (representing the plasma samples) were collected and stored at −80...
example 2
t of Chemotherapy on Circulating Host-Derived Pro-Tumorigenic Factors—a Protein Profiling Approach in Mice
[0129]To identify host-derived circulating factors whose levels change in response to chemotherapy, we performed protein array-based screens using plasma from naïve (non-tumor bearing) mice that were treated with different chemotherapy types. The use of naïve mice allows us to identify factors specifically generated by the host in response to chemotherapy, independent of tumor presence. To this end, naïve (non-tumor bearing) 8-10 week old female BALB / c mice (n=5) were treated with either FOLFOX (14 mg / kg oxaliplatin (Medac Pharma, Chicago, Ill., US); 50 mg / kg 5-fluorouracil (Ebewe Pharma, Vienna, Austria); 30 mg / kg folinic acid / leucovorin (ABIC, Israel)) or paclitaxel (BioAvenir Ltd., Israel; 25 mg / kg) chemotherapy administered as a single bolus intraperitoneal injection. Control mice (n=5) were injected with vehicle control. Twenty-four hours after treatment administration, mic...
example 3
t of Bortezomib on Circulating Host-Derived Pro-Tumorigenic Factors—a Protein Profiling Approach in Mice
[0130]The molecularly targeted drug, bortezomib (Velcade), is a proteasome inhibitor used for the treatment of multiple myeloma and mantle cell lymphoma. To identify host-derived circulating factors whose levels change in response to bortezomib, we performed a protein array-based screen using plasma from naïve (non-tumor bearing) mice that were treated with bortezomib. The use of naïve mice allows us to identify factors specifically generated by the host in response to bortezomib, independent of tumor presence.
[0131]Naïve (non-tumor bearing) 8-10 week old female BALB / c mice (n=5) were intravenously injected with 1 mg / kg bortezomib (Selleckchem, Houston, Tex., US). Control mice (n=5) were injected with vehicle control. Twenty-four hours after treatment administration, mice were sacrificed, and blood was collected into EDTA-coated tubes by cardiac puncture. Plasma was isolated by ce...
PUM
| Property | Measurement | Unit |
|---|---|---|
| time | aaaaa | aaaaa |
| time | aaaaa | aaaaa |
| time | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More